Myelodysplastic Syndrome Market Report 2025 (Global Edition)

Global Myelodysplastic Syndrome Market Report 2024 Market Size Split by Type Outlook: (Myelodysplastic Syndrome with Unilineage Dysplasia, Myelodysplastic Syndrome with Multilineage Dysplasia, Myelody...

Myelodysplastic Syndrome Market Report Description

We have various report editions of Myelodysplastic Syndrome Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Myelodysplastic Syndrome Market Insights Video

Competitive Landscape of the Myelodysplastic Syndrome Market

The market for myelodysplastic syndrome (MDS) is competitive, with major players emphasizing cutting-edge treatments such as targeted therapy and hypomethylating drugs. With cutting-edge drugs and strong R&D pipelines, major corporations like Takeda, Novartis, and Celgene (Bristol Myers Squibb) are at the forefront. Frequent mergers, strategic alliances, and collaborations fuel innovation. The rivalry is getting more intense as new biotech companies are also offering creative ideas. Regulatory approvals and geographic expansion further shape the competitive dynamics.

According to Syros Pharmaceuticals, 190 patients were enrolled in the SELECT-MDS-1 Phase 3 clinical trial in March 2024. The trial will assess tamibarotene in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. This initial cohort is necessary to provide the primary endpoint analysis for complete response (CR). (Source: https://ir.syros.com/press-releases/detail/298/syros-announces-completion-of-enrollment-of-190-patients) In February 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) approved Reblozyl for Bristol-Myers Squibb Company's use in the treatment of myelodysplastic syndromes. (Source:https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Reblozyl--luspatercept-for-Treatment-of-Adults-with-Transfusion-Dependent-Anemia-due-to-Low--to-Intermediate-Risk-Myelodysplastic-Syndromes-MDS/default.aspx) In September 2023, The US Food and Drug Administration (FDA) approved Akeso, Inc.'s application for an Investigational New Drug (IND) for AK117, a next-generation CD47 monoclonal antibody used in conjunction with azacitidine to treat patients with newly diagnosed higher-risk myelodysplastic syndromes. (Source: https://www.akesobio.com/en/media/akeso-news/230926/) In March 2022, In the United States, Teva Pharmaceutical Industries Ltd. introduced the first generic version of Revlimid capsules. Adult patients with myelodysplastic syndrome are treated with these prescription tablets. The company's business portfolio now has more value thanks to this tactic. (Source: https://www.tevapharm.com/news-and-media/latest-news/teva-announces-launch-of-a-first-generic-version-of-revlimid-lenalidomide-capsules-in-the-u.s/)

Top Companies Market Share in Myelodysplastic Syndrome Industry: (In no particular order of Rank)

• Amgen Inc.
• Astex Pharmaceuticals
• Inc.
• Hikma Pharmaceuticals PLC
• Johnson & Johnson Services
• Inc.
• Cipla Limited
• Dr. Reddy's Laboratories Inc.
• Lupin Limited
• Otsuka America Pharmaceutical
• Inc.
• Shilpa Medicare Limited
• Pfizer
• Inc.
• Sandoz
• Sun Pharmaceutical Industries
• Inc.
• Teva Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Company Limited
• Bristol-Myers Squibb Company (Celgene Corporation)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Myelodysplastic Syndrome Market

Which Region Dominates the Myelodysplastic Syndrome Market in 2024?

According to Cognitive Market Research, North America currently dominates the Myelodysplastic Syndrome market, and the region is expected to have significant growth during the projected period. Because of its sophisticated healthcare system and high rate of Myelodysplastic Syndrome (MDS) in the elderly population, North America is expected to propel the market's expansion. Access to cutting-edge therapies, including bone marrow transplants and hypomethylating drugs, as well as broad knowledge and early diagnosis, are advantageous to the area. The market is further supported by significant government funding for orphan medications and significant investments in R&D. Important pharmaceutical companies are aggressively introducing and growing their product lines in this area. A strong clinical trial network and advantageous reimbursement regulations are also contributing to North America's growing market dominance.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Asia Pacific's growing ageing population and evolving healthcare system are expected to drive a major increase in the market for myelodysplastic syndrome (MDS). As knowledge of MDS grows and diagnostic techniques improve, better treatment outcomes and earlier diagnosis are being made possible. Increases in healthcare spending and insurance coverage are improving access to innovative medications. Additionally, the increasing use of tailored medicine and targeted medications is expanding the options for treatment. In the future years, as pharmaceutical companies focus on expanding their presence in new areas, Asia Pacific is emerging as a key location for the growth of the MDS market.

The current report Scope analyzes Myelodysplastic Syndrome Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Myelodysplastic Syndrome

According to Cognitive Market Research, the global Myelodysplastic Syndrome market size was estimated at USD 3142.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1257.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Myelodysplastic Syndrome market with a market size of USD 991.77 million in 2024 and is projected to grow at a CAGR of 6.2% during the forecast period. Advanced diagnostic and treatment options for MDS, such as hypomethylating drugs, chemotherapy, and stem cell transplants, are available at US hospitals and speciality clinics.
• The Canadian Myelodysplastic Syndrome market had a market share of USD 150.84 million in 2024 and is projected to grow at a CAGR of 7.2% during the forecast period. Demand is fueled by the widespread availability of MDS therapies provided by Canada's publicly subsidized healthcare system.
• The Mexico Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 6.9% during the forecast period, with a market size of USD 114.39 million in 2024.

Europe Myelodysplastic Syndrome

According to Cognitive Market Research, the global Myelodysplastic Syndrome market size was estimated at USD 3142.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 942.75 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.

• The United Kingdom's Myelodysplastic Syndrome market had a market share of USD 158.38 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. In the UK, the NHS promotes treatment accessibility by offering a thorough framework for MDS diagnosis and management.
• The France Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 86.73 million in 2024.
• According to Cognitive Market Research, the German Myelodysplastic Syndrome market size was valued at USD 186.66 million in 2024 and is projected to grow at a CAGR of 6.9% during the forecast period. Clinical research is centred on Germany, which aids in the creation of innovative treatments for MDS.
• The Italy Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 81.08 million in 2024.
• The Russia Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 146.13 million in 2024.
• The Spain Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 5.8% during the forecast period with a market size of USD 77.31 million in 2024
• The Luxembourg Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 29.23 million in 2024.
• The Portugal Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 19.80 million in 2024.
• The Greece Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 11.31 million in 2024.
• The Rest of Europe's Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 5.4% during the forecast period, with a market size of USD 146.13 million in 2024.

Asia Pacific Myelodysplastic Syndrome

According to Cognitive Market Research, the global Myelodysplastic Syndrome market size was estimated at USD 3142.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 722.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Myelodysplastic Syndrome market size was valued at USD 325.25 million in 2024 and is projected to grow at a CAGR of 9.7% during the forecast period. Myelodysplastic Syndrome surged in China due to increased investments in medical technology and infrastructure, leading to improved options for diagnosing and treating MDS.
• The Japan Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 99.74 million in 2024.
• The India Myelodysplastic Syndrome market had a market share of USD 86.73 million in 2024 and is projected to grow at a CAGR of 12.0% during the forecast period. In India, increased demand for treatment and early diagnosis are the results of growing knowledge of hematological illnesses, including MDS.
• The South Korean Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 72.28 million in 2024.
• The Australian Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 9.9% during the forecast period, with a market size of USD 37.58 million in 2024.
• The South East Asia Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 49.87 million in 2024.
• The Rest of Asia Pacific Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 51.32 million in 2024.

South America Myelodysplastic Syndrome

According to Cognitive Market Research, the global Myelodysplastic Syndrome market size was estimated at USD 3142.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 157.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Myelodysplastic Syndrome market size was valued at USD 67.25 million in 2024 and is projected to grow at a CAGR of 8.2% during the forecast period. Myelodysplastic Syndrome flourished in Brazil due to the rising number of oncology centres, and Brazil's public healthcare system offers easily accessible MDS treatment choices.
• Argentina's Myelodysplastic Syndrome market had a market share of USD 26.40 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. Argentina's increased disposable incomes, driven forth by economic expansion, may allow patients to pay for cutting-edge treatments.
• Colombia's Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 7.4% during the forecast period, with a market size of USD 13.98 million in 2024.
• Peru's Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 12.88 million in 2024.
• Chile's Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 7.9% during the forecast period, with a market size of USD 11.31 million in 2024.
• The Rest of Latin America's Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 25.30 million in 2024.

Middle East and Africa Myelodysplastic Syndrome

According to Cognitive Market Research, the global Myelodysplastic Syndrome market size was estimated at USD 3142.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 62.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031..

• The GCC Countries Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 26.90 million in 2024. Myelodysplastic Syndrome sales flourish due to the GCC nations are increasingly becoming hubs for medical tourism, attracting patients from neighbouring countries for specialized MDS treatments.
• The Egypt Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 6.60 million in 2024.
• The South African Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 9.93 million in 2024. Myelodysplastic Syndrome sales flourished in South Africa due to the need for therapy is rising as a result of improved MDS detection rates brought about by government-led screening programs and growing awareness campaigns.
• The Turkey Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 7.4% during the forecast period, with a market size of USD 5.41 million in 2024.
• The Nigeria Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 6.60 million in 2024.
• The Rest of the MEA Myelodysplastic Syndrome market is projected to witness growth at a CAGR of 6.9% during the forecast period, with a market size of USD 7.42 million in 2024.

Myelodysplastic Syndrome Market Analysis

How are Segments Performing in the Global Myelodysplastic Syndrome Market?

Myelodysplastic Syndrome Market Type Segment Analysis

According to Cognitive Market Research, myelodysplastic syndrome with unilineage dysplasia is likely to dominate the Myelodysplastic Syndrome Market over the forecast period. Unilineage dysplasia, a variant of myelodysplastic syndrome (MDS), is typified by aberrant production of blood cells that affects only one cell lineage, such as platelets, white blood cells, or red blood cells. Patients with this illness frequently have mild to moderate cytopenias, which can include anemia or an elevated risk of bleeding and infection. Even though the prognosis for this type of MDS is generally better than for other subtypes, it still needs to be carefully managed and closely watched. The results for patients with this illness are getting better because of new therapy choices, such as hypomethylating medications.

The myelodysplastic syndrome with multilineage dysplasia is the fastest-growing segment in the Myelodysplastic Syndrome Market. Multilineage dysplasia is a variant of myelodysplastic syndrome (MDS) in which abnormalities impact red blood cells, white blood cells, and platelets, among other blood cell lineages. Patients with this illness frequently develop more severe cytopenias, exhibiting severe symptoms such as bleeding, anemia, and recurrent infections. The prognosis for MDS with multilineage dysplasia is typically worse than for unilineage dysplasia because of the disorder's intricacy. The condition is managed, and patient outcomes are improved with treatment choices like bone marrow transplants, chemotherapy, and hypomethylating medications, but the prognosis is still difficult.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Myelodysplastic Syndrome Industry. Request a Free Sample PDF!

Myelodysplastic Syndrome Market Therapeutic Class Segment Analysis

According to Cognitive Market Research, the hypomethylating agents segment holds the largest share of the market. Because hypomethylating agents are successful in treating high-risk MDS and improving patient outcomes, there is a strong demand for them in the Myelodysplastic Syndrome (MDS) market. By reactivating tumour suppressor genes and preventing aberrant cell proliferation, medications such as decitabine and azacitidine, which are important hypomethylating drugs, enhance the formation of blood cells. For patients with severe disease stages or those who are not candidates for stem cell transplantation, these medicines are very crucial. Demand for the MDS therapeutic class is rising due to its capacity to increase survival and slow the development of the disease, particularly in North America and Europe.

In the Myelodysplastic Syndrome Market, immunomodulatory drugs have been expanding at a rapid pace. Because immunomodulatory medicines (IMiDs) are helpful in treating low-risk MDS, particularly in individuals with specific genetic abnormalities, their demand in the Myelodysplastic Syndrome (MDS) market is increasing. Lenalidomide is one medication that is frequently used to treat MDS linked to chromosome 5q deletion; it has been shown to boost red blood cell formation and decrease reliance on transfusions. By influencing the immune system and encouraging hematopoiesis, IMiDs provide patients with a focused therapeutic option. Immunomodulatory medications are projected to become more and more in demand for treating MDS as long as clinical data continues to support their effectiveness, especially in regions like North America and Europe.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Myelodysplastic Syndrome Treatment Outlook: Segment Analysis

Myelodysplastic Syndrome Market Treatment Segment Analysis

According to Cognitive Market Research, the chemotherapy segment holds the largest share of the market. Chemotherapy is still in great demand in the market for myelodysplastic syndrome (MDS), especially for the treatment of high-risk MDS or instances that develop into acute myeloid leukemia (AML). Chemotherapeutic drugs, like anthracyclines and cytarabine, are used to lower blast cell levels and slow the course of the disease. Chemotherapy is still a vital alternative for patients who are not eligible for more sophisticated treatments like bone marrow transplants, even with the advent of targeted medicines. Demand is also being driven by the increasing incidence of MDS and improvements in combination regimens, particularly in areas with established cancer treatment systems.

In the Myelodysplastic Syndrome Market, stem cell transplants have been expanding at a rapid pace. Because stem cell transplantation is still the only cure for Myelodysplastic Syndrome (MDS), especially in younger and high-risk patients, the market for these transplants is expanding. Through hematopoietic stem cell transplantation (HSCT), the disease's underlying cause is efficiently addressed by substituting healthy donor cells for the patient's damaged bone marrow. The eligibility of older patients has been increased due to improvements in supportive care and advancements in transplant methods. Its acceptance is, however, somewhat constrained by issues such as donor availability and transplant-related problems. It is anticipated that greater awareness and the creation of stem cell registries will increase demand worldwide, especially in industrialized areas.

• Supportive Therapy
• Chemotherapy
• Stem Cell Transplant
• Others

Myelodysplastic Syndrome Route of Administration Outlook: Segment Analysis

Myelodysplastic Syndrome Market Route of Administration Segment Analysis

According to Cognitive Market Research, the injectable segment holds the largest share of the market. Because injectables are effective at delivering treatments, including hypomethylating drugs, chemotherapy, and supportive care medications, there is still a considerable demand for them in the Myelodysplastic Syndrome (MDS) market. For medications like azacitidine and decitabine, intravenous and subcutaneous injections are frequently utilized, guaranteeing accurate dosing and quick absorption. When treating moderate-to-high-risk MDS cases that need intensive care, this approach is essential. Injectables remain the preferred option for hospital-based therapies and in areas where sophisticated oral formulations are less readily available, even with the growing popularity of oral alternatives.

In the Myelodysplastic Syndrome Market, oral has been expanding at a rapid pace. Because oral route delivery is more convenient and improves patient compliance compared to traditional intravenous approaches, it is becoming more and more popular in the Myelodysplastic Syndrome (MDS) market. Oral hypomethylating medications, such as oral azacitidine, have drawn interest because they enable patients to take care of their therapy at home, which lowers hospital stays and medical expenses. For older MDS patients who might have mobility issues, this method is especially helpful. Demand is being driven, particularly in developed nations with sophisticated healthcare infrastructure, by the growing desire for outpatient treatments and continuous advancements in oral formulations.

• Oral
• Injectable
• Others

Myelodysplastic Syndrome End-Users Outlook: Segment Analysis

Myelodysplastic Syndrome Market End-Users Segment Analysis

According to Cognitive Market Research, the hospital segment holds the largest share of the market. In the market for Myelodysplastic Syndrome (MDS), hospitals are essential because they are the main locations for diagnosis, treatment, and aftercare. Complex medicines that call for specific infrastructure and knowledge, such as stem cell transplants, hypomethylating drugs, and chemotherapy, can be administered by them. Acute myeloid leukemia (AML) and high-risk MDS are among the important cases that hospitals treat. Multidisciplinary care teams and the availability of sophisticated diagnostic techniques only serve to increase their significance. Hospitals' demand in the worldwide MDS market is being driven by an increase in patient influx due to the rising prevalence of MDS.

In the Myelodysplastic Syndrome Market, speciality centres have been expanding at a rapid pace. In the market for Myelodysplastic Syndrome (MDS), speciality centres are becoming important end users by providing patients with MDS with specialized and all-encompassing care. These facilities have specialist personnel, cutting-edge diagnostic equipment, and focused treatments such as immunomodulatory medications, hypomethylating medicines, and access to clinical trials. They offer supportive care and individualized treatment strategies for both low- and high-risk MDS cases. The need for speciality centres is being driven by improvements in treatment modalities and the growing desire for specialized, patient-centred care, especially in developed areas with strong healthcare infrastructure.

• Hospitals
• Homecare
• Speciality Centres
• Others

Myelodysplastic Syndrome Distribution Channel Outlook: Segment Analysis

Myelodysplastic Syndrome Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the hospital pharmacy segment holds the largest share of the market. In the market for Myelodysplastic Syndrome (MDS), hospital pharmacists play a crucial role in distributing necessary treatments such as supportive care pharmaceuticals, hypomethylating agents, and chemotherapy medications. These pharmacies handle the complicated drug requirements of MDS patients, serving both inpatients and outpatients. They are essential in administering expensive and specialized medications while guaranteeing appropriate administration and management. Because hospitals serve as the main MDS treatment facilities, there is a growing need for hospital pharmacies as a distribution route, especially in areas with more developed healthcare systems and rising MDS prevalence.

In the Myelodysplastic Syndrome Market, online pharmacies have been expanding at a rapid pace. The Myelodysplastic Syndrome (MDS) market is seeing a surge in the use of online pharmacies because of its accessibility and ease of use. Patients, especially those who need long-term treatments like supportive care medications and hypomethylating medicines, benefit from online platforms' competitive prices and home delivery choices. Prescription fulfilment may now be seamlessly integrated into online pharmacies because of the growing use of telemedicine and digital healthcare. Particularly in areas with restricted access to physical healthcare facilities, online pharmacies are becoming a preferred avenue as awareness and internet usage rise globally.

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion